Humasis Co Ltd

Humasis operates with a liquidity position that is relatively strong, as evidenced by a current ratio of 2.43 and cash and equivalents of KRW 15.64 billion. However, the company's price-to-book ratio of 0.42 and price-to-tangible-book ratio of 0.42 suggest that the market values the company below its book value, indicating potential undervaluation or financial distress. Profitability metrics are concerning, with a return on equity (ROE) of -7.26% and a return on assets (ROA) of -4.78%, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of KRW 15.62 billion and an operating loss of KRW 18.83 billion, reflecting operational inefficiencies or market pressures. The company's revenue is derived from a mix of domestic and international markets, though the exact geographic breakdown is not disclosed. Given the nature of the diagnostic device industry, Humasis is likely exposed to regulatory and reimbursement dynamics in key markets, which could affect its revenue stability. Growth prospects appear muted, with no significant revenue growth reported in the latest financial period. The company's free cash flow is negative at KRW -19.38 billion, and capital expenditures are modest at KRW -443.09 million, suggesting limited reinvestment in growth initiatives. Risk factors include the company's negative net income and operating income, which could pressure liquidity if cash flow from operations declines. The debt-to-equity ratio of 0.06 is low, but the negative net income could increase leverage if not addressed. No immediate dilution risks are flagged, and the number of shares outstanding remains unchanged between basic and diluted shares. Recent filings and transcripts do not indicate any material events or strategic shifts. The company continues to focus on its core diagnostic device business, with no disclosed major R&D or M&A activity in the latest period.